Inpart’s latest report provides access to the most promising biotech assets and discovery platforms, shedding light on the latest trends in biotech R&D.
This week, we have a conversation with Alessandro Toniolo, CEO of Resalis Therapeutics, about a non-coding RNA drug candidate that promotes sustainable weight loss.